X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CT-P39 (omalizumab) is a monoclonal antibody that inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils. It is being developed as a biosimilar candidate to XOLAIR® approved to treat chronic spontaneous urticaria.
Lead Product(s): Omalizumab
Therapeutic Area: Immunology Product Name: CT-P39
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2024
Details:
Remsima (infliximab) blocks the action of TNF-alpha. It is approved for maintenance therapy in adults with moderately to severely active ulcerative colitis and crohn’s disease.
Lead Product(s): Infliximab
Therapeutic Area: Gastroenterology Product Name: Remsima
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2024
Details:
CT-P47 (tocilizumab-biosimilar) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. It is being evaluated in phase 3 clinical trials for the treatment of moderate to severe active rheumatoid arthritis.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: CT-P47
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2024
Details:
Zymfentra is the first and only FDA-approved subcutaneous (SC) formulation of infliximab approved for the maintenance treatment of adult patients with moderately to severely active ulcerative colitis and Crohn’s disease.
Lead Product(s): Infliximab-dyyb
Therapeutic Area: Gastroenterology Product Name: Zymfentra
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
Yuflyma (adalimumab-aaty) is the world’s first proposed high-concentration, low-volume and citrate-free adalimumab biosimilar to receive European Commission approval in Europe. Yuflyma is FDA approved for the treatment of autoimmune conditions.
Lead Product(s): Adalimumab-aaty
Therapeutic Area: Immunology Product Name: Yuflyma
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
Under the agreement, Celltrion will exclusively supply to Rani the adalimumab biosimilar drug substance (CT-P17) required for the development of RT-105, an oral capsule containing a TNF-α inhibitor antibody being developed for the treatment of psoriatic arthritis.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: RT-105
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rani Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 05, 2023
Details:
Yuflyma (adalimumab-aaty) is the world’s first proposed high-concentration, low-volume and citrate-free adalimumab biosimilar to receive European Commission approval in Europe. Yuflyma is FDA approved for the treatment of autoimmune conditions.
Lead Product(s): Adalimumab-aaty
Therapeutic Area: Immunology Product Name: Yuflyma
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.
Lead Product(s): CT-G20
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CT-G20
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Bora Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 06, 2023
Details:
Under the agreement, Celltrion and LISCure intend to develop, oral LBPs, microbiome-based therapies, for Parkinson's disease. LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases based on its platform technology.
Lead Product(s): Microbiome-based Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: LISCure Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2023
Details:
Rani is granted an exclusive license to use CT-P43 in the development and commercialization of RT-111, an orally administered ustekinumab biosimilar and Celltrion is granted a right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: RT-111
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Rani Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
